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Conclusion: Our study demonstrates that the pelvic lymph 
nodes receive a significant dose contribution from 
brachytherapy in cervical cancer, when employing the 
Manchester prescription system. This must be taken into 
account during external beam radiotherapy planning, and 
adequate external beam boost doses calculated to achieve 
cumulative tumoricidal doses to pelvic nodal disease.  
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Purpose or Objective: Endometrial cancer is the mainly 
gynaecologic malignancy, 80-85% in stage I at diagnosis. The 
standard primary treatment remains TAH&BSO, with 
appropriate surgical staging. The epidemiology of this disease 
favours elderly, obese women with multiple medical 
problems (hypertension, diabetes, cardiovascular diseases, 
coagulation disorders, respiratory disorders) that render 
some of them medically inoperable. RT alone is the only 
efficient option for these women. BT is the main component 
in this cohort of patients (pts). 
 
Material and Methods: September 1997-September 2015: 90 
pts RT alone, 71 BT HDR alone. Median age 79 years (range 
57-93). Staging: clinical examination, TVUS, MR or CT scan 
and fractionated curettage. Stage Ia 32 pts, Stage Ib 36 pts, 
Stage II 3 pts. OS, DSS, LC and late side effects were analysed 
retrospectively. Follow-up > 10 years (mean 57 months). BT 
HDR with Rotte “Y” applicator, plus VBT in stage II. Dose 
prescription at ‘‘uterine points’’ that are two points located 
1 cm over the middle of a line drawn between the tips of the 
two ends of the "Y" applicator and at series of points placed 
laterally to the tandem according to the pre-treatment 
imaging data. We treat the entire length of the uterus to 
ensure coverage of the fund. To maintain the bladder and 
rectal maximum point doses below 100% of the prescribed 
dose we optimize with TPS. Until 2002 BT was performed 4-5 
times, weekly, mean dose 29.3 Gy (range 18-35 Gy); from 
2003 (42 pts) we deliver 30 Gy in five frs, 6 Gy each b.i.d. 
schedule, 6 hours interval between frs. 
 
Results: 5 years OS, DSS and LC: 52.1%, 85.9%, and 91.2%. 
Stage Ia: 56.3%, 87.5%, and 90.6%; Stage Ib: 50%, 86.1%, 
and 94.4%; Stage II: 33.3%, 66.7%, and 66.7%. DSS was not 
affected by tumour grade or age. One patient had a PD, 6 
(10.6%) developed recurrence after a median of 13 months (3 
with distant metastases), 2 (3.5%) a lymph node recurrence 
with distant metastases. One patient have a GE grade III late 
side effect (1.8%) at 5 years, not related with rectal dose. 
 
Conclusion: HDR BT with “Y” applicator is a very effective 
treatment modality with good LC rates and suitable DSS for 
pts who are not fit for surgery. This technique has proven to 
have a low risk of acute complications and long-term side 
effects. Longer follow-up will be required to document the 
incidence of late effects using the b.i.d. schedule. In the 
short term, it seems that this approach is a feasible way to 
limit the number of procedural complications and length of 
hospital stay and bed rest. 
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Purpose or Objective: Basal cell carcinoma (BCC) is a very 
common cancer in the Caucasian population. Treatment aims 
to eradicate the tumor with the lowest possible functional 
and aesthetic impact. Electronic brachytherapy (EBT) is a 
treatment technique currently emerging. This study aims to 
show the outcomes of two consecutive prospective pilot 
clinical trials using different radiation doses of EBT with 
Esteya® EB system for the treatment of superficial and 
nodular basal cell carcinoma. 
 
Material and Methods: Two prospective, single-center, non-
randomized, pilot studies were conducted. Twenty patients 
were treated in each study with different doses. The first 
group (1) was treated with 36.6 Gy in 6 fractions of 6.1 Gy 
and the second group (2) with 42 Gy in 6 fractions of 7 Gy. In 
one case the 6.1 Gy/fraction resulting from the theorical RBE 
calculation was used, and in the second arm (7 Gy/fraction) 
the same dose as the Valencia applicator study was used. 
Cure rate, acute toxicity and late toxicity related to cosmesis 
were analyzed in the two treatment groups.  
 
Results: In group 1, a complete response in 90% of cases was 
observed at the 1 year follow-up, whereas in group 2 the 
complete response was 95%. Tumor persistence or recurrence 
was suspected clinically and dermoscopically in two patients 
in the first group at 3 and 6 months respectively and in one 
patient in the second group at 1 year follow-up. The 
differences with reference to acute toxicity and the cosmetic 
results between the two treatment groups were not 
statistically significant.  
 
Conclusion: Our initial experience with Esteya® EB system to 
treat superficial and nodular BCC shows that a dose of 36.6 
Gy and 42 Gy delivered in 6 fraction of 7 Gy achieves a 90% 
and 95% clinical cure rate at 1 year respectively. Both groups 
had a tolerable toxicity and a very good cosmesis. 
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Purpose or Objective: Feasibility and dosimetric study of 3D-
printed cylindrical and skin mould applicators for High Dose 
Rate brachytherapy (HDR-BRT) using acrylonitrile butadiene 
styrene (ABS). 
 
Material and Methods: Three cylindrical applicators (1 as 
reference and 2 as test) with a single 2.5 mm catheter 
channel and a 1 mm radial slit for radiochromic film support 
were 3D printed (HP3DX100, Hamlet, Dublin, IE) using ABS 
plastic. The reference had the radiochromic slit in contact 
